Developer docs
API playgroundTry for free, no card

Search company profiles

Essential Pharma

Full company profile

uuid0000kir

Namestring
Essential Pharma
Legal namestring
Essential Holdings Limited
Company typeenum
Private
Founded yearint
1985
Descriptiontext

Essential Pharma is a privately held specialty pharmaceutical company headquartered in Egham, Surrey, UK, focused on acquiring, maintaining, and commercialising clinically differentiated medicines that serve small, underserved, or rare disease patient populations across approximately 70 countries. Founded around 1985 and backed by Swiss private equity firm Gyrus Capital since a 2020 management buyout, the company operates a portfolio of more than 35 products spanning 12 therapeutic areas — with particular depth in CNS, ophthalmology, gastroenterology, cardiovascular, dermatology, and rare disease. Its core business model is the acquisition of mature, at-risk-of-discontinuation assets divested by larger pharmaceutical companies (notably from Novartis, Teva, Bayer, and Rosemont Pharmaceuticals), combined with selective development of novel therapies for high-unmet-need indications.

The company's commercial engine combines direct sales operations in five European jurisdictions (UK, France, Malta, Switzerland, Spain) with regional distribution partnerships — Clinigen for JAPAC and AcedrA Biopharmaceuticals for MENA. Pricing is not publicly disclosed but is negotiated through regional reimbursement frameworks typical of niche specialty pharmaceuticals. In April 2024 the company made its most significant strategic shift by acquiring Renaissance Pharma Ltd, introducing its first development-stage asset: Daretabart (hu1418K322A), a structurally modified anti-GD2 monoclonal antibody for high-risk neuroblastoma licensed exclusively from St. Jude Children's Research Hospital, which received FDA Fast Track Designation and IND clearance in April 2026. Essential Pharma is organised into Established Brands and Rare Disease business units, led by a senior team drawn from Jazz Pharmaceuticals, GSK, EUSA Pharma, Alexion, and Catalent. A €900 million recapitalisation in December 2024 led by AlpInvest and Sixth Street provides capital for continued acquisitions and pipeline expansion.

Short descriptiontext

Essential Pharma is a UK-based privately held specialty pharmaceutical company that acquires, maintains, and commercialises clinically differentiated, at-risk medicines for small and rare disease patient populations across approximately 70 countries, with a growing development pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEgham, United Kingdom
HQ citystring
Egham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, rare disease medicines, essential medicines supply, niche therapeutics, pharmaceutical acquisitions
Industry6 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Essential Pharma generates revenue through the sale and commercialization of acquired specialty pharmaceutical products across multiple therapeutic areas including rare disease, CNS, ophthalmology, and gastroenterology. Products are sold in approximately 70 countries through direct sales and distribution partners.

essentialpharmagroup.com
2In-licensing and Out-licensing
TypeLicensing Royalties
Description

The company enters into licensing arrangements for products, including in-licensing arrangements for development-stage and commercial products, and out-licensing to maximize value of assets while ensuring patient access.

essentialpharmagroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Essential Pharma acquires, manufactures and commercializes clinically differentiated, niche branded pharmaceutical medicines that are at risk of discontinuation by larger pharmaceutical companies, serving small, underserved and rare disease patient populations across approximately 70 countries. The portfolio spans more than 35 products across 12 therapeutic areas (rare disease, CNS, ophthalmology, gastroenterology, cardiovascular, dermatology, endocrinology, gynaecology, infectious diseases, rheumatology). In parallel, the company is developing its first clinical-stage asset, Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody for high-risk neuroblastoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Daretabart demonstrated 73.7% 3-year event-free survival and 86.0% overall survival in Phase II trials for high-risk neuroblastoma
+1 more record
Product and service7 records
1Ventavis (iloprost trometamol)
CategoryRare disease - Pulmonary Hypertension
Description

Inhaled iloprost therapy used to treat adult primary pulmonary hypertension; marketed to specialist pulmonary vascular centers in over 60 markets globally.

2Daretabart (hu1418K322A)
CategoryRare disease - Oncology Biologics Pipeline
Description

Novel anti-GD2 monoclonal antibody in clinical development for high-risk neuroblastoma (7–10% of all childhood cancers); held under exclusive license from St. Jude Children's Research Hospital via subsidiary Renaissance Pharma.

3Iopidine
CategoryOphthalmology
Description

Ophthalmic product for the adjunctive treatment of glaucoma, sold to eye care specialists across markets outside the US and India.

4Methergine
CategoryGynaecology
Description

Established therapy for the treatment of post-partum hemorrhage, distributed to obstetric and maternity healthcare providers across markets outside the US and India.

5Colobreathe (colistimethate sodium)
CategoryInfectious Diseases / Cystic Fibrosis
Description

Inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients; sold to respiratory and CF treatment centers across Europe.

6Reminyl (galantamine hydrobromide) oral capsules
CategoryCNS / Alzheimer's Disease
Description

Established CNS therapy for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type; prescribed by neurologists and geriatric specialists.

7Priadel
CategoryCNS
Description

Established lithium-based CNS therapy supplied to the UK market as an essential medicine for eligible patient populations.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Acquisition of Ventavis (iloprost trometamol) and Breelib nebuliser delivery technology from Bayer AG, expanding Essential Pharma's rare disease franchise. Rights acquired across all global markets excluding USA and Russia.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-01
Description

Expanded collaboration to improve patient access in JAPAC region. Drives continued patient access to four important therapies in Japan and Korea, strengthening combined market presence.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-07-01
Description

Campaign to donate life-saving medicines to disaster-hit countries. Donations to help support over 30,000 patients in disaster-hit and vulnerable communities worldwide.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-06-11
Description

Manufacturing agreement for late phase clinical manufacturing of immunotherapy candidate (Daretabart) for high-risk neuroblastoma treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-09
Description

Acquisition of Renaissance Pharma Ltd, a UK-based biopharmaceutical company developing anti-GD2 antibody (Hu14.18) for neuroblastoma treatment. Focus on advancing EU/US market approval of Phase II candidate.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-03-26
Description

Distribution agreement to commercialize essential medicines in the Middle East and North Africa region.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Acquisition of European rights to Colobreathe (colistimethate sodium), an inhaled antibiotic for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-12-16
Description

Acquisition of worldwide rights (excluding US and India) to Iopidine for glaucoma treatment and Methergine for post-partum haemorrhage from Novartis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive license agreement for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody for high-risk neuroblastoma. The antibody targets GD2, a cell surface antigen highly expressed on neuroblastoma cells.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global specialty and generics pharma formed by the Mylan-Pfizer Upjohn merger, with a large established-brand and off-patent specialty portfolio. Essential Pharma's Established Brands President previously served as Country Manager Switzerland/Liechtenstein at Viatris, and the companies address overlapping customers in mature specialty categories.

TypeDirect peer
Description

UK-based specialty pharma focused on women's health and other niche therapeutic areas, built largely through product acquisitions from larger pharma. Comparable niche-portfolio strategy and target-therapeutic mix (e.g., Methergine for postpartum hemorrhage overlaps with Essential Pharma's gynecology franchise).

TypeBroad incumbent
Description

South African-headquartered specialty pharma with a global portfolio in branded generics, specialty branded, and rare-disease medicines. Comparable as a platform that has built scale through large pharma divestments and operates a similar established-brand plus specialty mix.

TypeDirect peer
Description

UK-headquartered specialty pharma focused on accessing, registering, and distributing niche and at-risk medicines. Closely comparable operating model, with overlapping therapeutic areas and a direct commercial partnership with Essential Pharma in JAPAC.

TypeEmerging player
Description

US-headquartered rare-disease specialty pharma with a portfolio of niche therapies for underserved populations. Essential Pharma's interim CEO previously served as Global Head of Business Development at Leadiant, and the two share a rare-disease and specialty-orphan commercial focus.

TypeBroad incumbent
Description

Specialty pharma with a CNS, rare disease, and sleep-medicine focus, built significantly through acquisitions (including EUSA Pharma in 2012). Multiple Essential Pharma executives previously worked at Jazz, and the company is a direct reference point for the EUSA-style growth playbook.

TypeBroad incumbent
Description

Danish specialty pharma with a dermatology-led portfolio and growing rare-disease presence. One of Essential Pharma's VPs previously held senior commercial roles at Leo, and the two share a European specialty-pharma orientation.

TypeBroad incumbent
Description

Privately held specialty pharma with established-brand and specialty portfolios across pain, oncology, and rare disease. One of Essential Pharma's M&A leaders previously held business development roles at Mundipharma, and the companies share a niche-portfolio and European distribution model.

TypeBroad incumbent
Description

Swedish-listed rare-disease specialty pharma with a portfolio of niche and orphan therapies across multiple therapeutic areas, including immunology. Comparable in rare-disease focus, geographic mix (predominantly Europe/US), and bolt-on M&A strategy.

TypeBroad incumbent
Description

Italian specialty pharma group with a strong rare disease and established-brand portfolio across Europe. Acquired EUSA Pharma for €750M in 2022 (founded by Essential Pharma's current Chairman and CEO) and is a direct comparator on business model and exit pathway.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Essential Pharma

Specialty Pharmaceuticalsessentialpharmagroup.com

Essential Pharma is a UK-based privately held specialty pharmaceutical company that acquires, maintains, and commercialises clinically differentiated, at-risk medicines for small and rare disease patient populations across approximately 70 countries, with a growing development pipeline.

What Essential Pharma does

Essential Pharma is a privately held specialty pharmaceutical company headquartered in Egham, Surrey, UK, focused on acquiring, maintaining, and commercialising clinically differentiated medicines that serve small, underserved, or rare disease patient populations across approximately 70 countries. Founded around 1985 and backed by Swiss private equity firm Gyrus Capital since a 2020 management buyout, the company operates a portfolio of more than 35 products spanning 12 therapeutic areas — with particular depth in CNS, ophthalmology, gastroenterology, cardiovascular, dermatology, and rare disease. Its core business model is the acquisition of mature, at-risk-of-discontinuation assets divested by larger pharmaceutical companies (notably from Novartis, Teva, Bayer, and Rosemont Pharmaceuticals), combined with selective development of novel therapies for high-unmet-need indications.

The company's commercial engine combines direct sales operations in five European jurisdictions (UK, France, Malta, Switzerland, Spain) with regional distribution partnerships — Clinigen for JAPAC and AcedrA Biopharmaceuticals for MENA. Pricing is not publicly disclosed but is negotiated through regional reimbursement frameworks typical of niche specialty pharmaceuticals. In April 2024 the company made its most significant strategic shift by acquiring Renaissance Pharma Ltd, introducing its first development-stage asset: Daretabart (hu1418K322A), a structurally modified anti-GD2 monoclonal antibody for high-risk neuroblastoma licensed exclusively from St. Jude Children's Research Hospital, which received FDA Fast Track Designation and IND clearance in April 2026. Essential Pharma is organised into Established Brands and Rare Disease business units, led by a senior team drawn from Jazz Pharmaceuticals, GSK, EUSA Pharma, Alexion, and Catalent. A €900 million recapitalisation in December 2024 led by AlpInvest and Sixth Street provides capital for continued acquisitions and pipeline expansion.

Essential Pharma firmographics

Firmographics
Name
Essential Pharma
Legal name
Essential Holdings Limited
Website
https://essentialpharmagroup.com
Company type
Private
Founded year
1985
Operating status
Operating
Headcount range
101–250 employees
Short description
Essential Pharma is a UK-based privately held specialty pharmaceutical company that acquires, maintains, and commercialises clinically differentiated, at-risk medicines for small and rare disease patient populations across approximately 70 countries, with a growing development pipeline.
Ownership category
akta.pro rank

Essential Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Specialty pharmaceuticals
  • Rare disease medicines
  • Essential medicines supply
  • Niche therapeutics
  • Pharmaceutical acquisitions

Where Essential Pharma is headquartered

Location

Headquarters

HQ city
Egham
HQ country
United Kingdom
HQ region
Europe

Offices5 records

Markets served

Essential Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Essential Pharma generates revenue through the sale and commercialization of acquired specialty pharmaceutical products across multiple therapeutic areas including rare disease, CNS, ophthalmology, and gastroenterology. Products are sold in approximately 70 countries through direct sales and distribution partners.
  2. In-licensing and Out-licensing: The company enters into licensing arrangements for products, including in-licensing arrangements for development-stage and commercial products, and out-licensing to maximize value of assets while ensuring patient access.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Essential Pharma product offering

Product offering

Core offering

Essential Pharma acquires, manufactures and commercializes clinically differentiated, niche branded pharmaceutical medicines that are at risk of discontinuation by larger pharmaceutical companies, serving small, underserved and rare disease patient populations across approximately 70 countries. The portfolio spans more than 35 products across 12 therapeutic areas (rare disease, CNS, ophthalmology, gastroenterology, cardiovascular, dermatology, endocrinology, gynaecology, infectious diseases, rheumatology). In parallel, the company is developing its first clinical-stage asset, Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody for high-risk neuroblastoma.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ventavis (iloprost trometamol) Inhaled iloprost therapy used to treat adult primary pulmonary hypertension; marketed to specialist pulmonary vascular centers in over 60 markets globally.
  • Daretabart (hu1418K322A) Novel anti-GD2 monoclonal antibody in clinical development for high-risk neuroblastoma (7–10% of all childhood cancers); held under exclusive license from St. Jude Children's Research Hospital via subsidiary Renaissance Pharma.
  • Iopidine Ophthalmic product for the adjunctive treatment of glaucoma, sold to eye care specialists across markets outside the US and India.
  • Methergine Established therapy for the treatment of post-partum hemorrhage, distributed to obstetric and maternity healthcare providers across markets outside the US and India.
  • Colobreathe (colistimethate sodium) Inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients; sold to respiratory and CF treatment centers across Europe.
  • Reminyl (galantamine hydrobromide) oral capsules Established CNS therapy for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type; prescribed by neurologists and geriatric specialists.
  • Priadel Established lithium-based CNS therapy supplied to the UK market as an essential medicine for eligible patient populations.

Quantifiable outcome

  • Daretabart demonstrated 73.7% 3-year event-free survival and 86.0% overall survival in Phase II trials for high-risk neuroblastoma
  • +1 more outcomes

Companies that use Essential Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Essential Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Essential Pharma partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • Bayer AGcoreStrategic or Co-development Partner · 17 February 2026Acquisition of Ventavis (iloprost trometamol) and Breelib nebuliser delivery technology from Bayer AG, expanding Essential Pharma's rare disease franchise. Rights acquired across all global markets excluding USA and Russia.
  • ClinigenmajorChannel Partner/ Reseller/ Distributor · 1 February 2025Expanded collaboration to improve patient access in JAPAC region. Drives continued patient access to four important therapies in Japan and Korea, strengthening combined market presence.
  • International Health PartnersminorGTM or Marketing Partner · 1 July 2024Campaign to donate life-saving medicines to disaster-hit countries. Donations to help support over 30,000 patients in disaster-hit and vulnerable communities worldwide.
  • AGC BiologicscoreImplementation/ SI/ Consulting Partner · 11 June 2024Manufacturing agreement for late phase clinical manufacturing of immunotherapy candidate (Daretabart) for high-risk neuroblastoma treatment.
  • Renaissance Pharma LtdcoreStrategic or Co-development Partner · 9 April 2024Acquisition of Renaissance Pharma Ltd, a UK-based biopharmaceutical company developing anti-GD2 antibody (Hu14.18) for neuroblastoma treatment. Focus on advancing EU/US market approval of Phase II candidate.
  • AcedrA BiopharmaceuticalsmajorChannel Partner/ Reseller/ Distributor · 26 March 2024Distribution agreement to commercialize essential medicines in the Middle East and North Africa region.
  • TevamajorStrategic or Co-development Partner · 1 January 2024Acquisition of European rights to Colobreathe (colistimethate sodium), an inhaled antibiotic for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients.
  • NovartismajorStrategic or Co-development Partner · 16 December 2021Acquisition of worldwide rights (excluding US and India) to Iopidine for glaucoma treatment and Methergine for post-partum haemorrhage from Novartis.
  • St. Jude Children's Research HospitalcoreStrategic or Co-development PartnerExclusive license agreement for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody for high-risk neuroblastoma. The antibody targets GD2, a cell surface antigen highly expressed on neuroblastoma cells.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Essential Pharma competitors and assessment

Company assessment

Broad incumbents

  • Viatris: Global specialty and generics pharma formed by the Mylan-Pfizer Upjohn merger, with a large established-brand and off-patent specialty portfolio. Essential Pharma's Established Brands President previously served as Country Manager Switzerland/Liechtenstein at Viatris, and the companies address overlapping customers in mature specialty categories.
  • Aspen Pharmacare: South African-headquartered specialty pharma with a global portfolio in branded generics, specialty branded, and rare-disease medicines. Comparable as a platform that has built scale through large pharma divestments and operates a similar established-brand plus specialty mix.
  • Jazz Pharmaceuticals: Specialty pharma with a CNS, rare disease, and sleep-medicine focus, built significantly through acquisitions (including EUSA Pharma in 2012). Multiple Essential Pharma executives previously worked at Jazz, and the company is a direct reference point for the EUSA-style growth playbook.
  • Leo Pharma: Danish specialty pharma with a dermatology-led portfolio and growing rare-disease presence. One of Essential Pharma's VPs previously held senior commercial roles at Leo, and the two share a European specialty-pharma orientation.
  • Mundipharma: Privately held specialty pharma with established-brand and specialty portfolios across pain, oncology, and rare disease. One of Essential Pharma's M&A leaders previously held business development roles at Mundipharma, and the companies share a niche-portfolio and European distribution model.
  • Swedish Orphan Biovitrum (Sobi): Swedish-listed rare-disease specialty pharma with a portfolio of niche and orphan therapies across multiple therapeutic areas, including immunology. Comparable in rare-disease focus, geographic mix (predominantly Europe/US), and bolt-on M&A strategy.
  • Recordati: Italian specialty pharma group with a strong rare disease and established-brand portfolio across Europe. Acquired EUSA Pharma for €750M in 2022 (founded by Essential Pharma's current Chairman and CEO) and is a direct comparator on business model and exit pathway.

Direct peers

  • Theramex: UK-based specialty pharma focused on women's health and other niche therapeutic areas, built largely through product acquisitions from larger pharma. Comparable niche-portfolio strategy and target-therapeutic mix (e.g., Methergine for postpartum hemorrhage overlaps with Essential Pharma's gynecology franchise).
  • Clinigen Group: UK-headquartered specialty pharma focused on accessing, registering, and distributing niche and at-risk medicines. Closely comparable operating model, with overlapping therapeutic areas and a direct commercial partnership with Essential Pharma in JAPAC.

Emerging players

  • Leadiant Biosciences: US-headquartered rare-disease specialty pharma with a portfolio of niche therapies for underserved populations. Essential Pharma's interim CEO previously served as Global Head of Business Development at Leadiant, and the two share a rare-disease and specialty-orphan commercial focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Essential Pharma social profiles

Digital presence

Essential Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Essential Pharma leadership team

Management profile

Number of profiles

Profiles16 records

Essential Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Essential Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Essential Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Essential Pharma

What does Essential Pharma do?

Essential Pharma acquires, manufactures and commercializes clinically differentiated, niche branded pharmaceutical medicines that are at risk of discontinuation by larger pharmaceutical companies, serving small, underserved and rare disease patient populations across approximately 70 countries. The portfolio spans more than 35 products across 12 therapeutic areas (rare disease, CNS, ophthalmology, gastroenterology, cardiovascular, dermatology, endocrinology, gynaecology, infectious diseases, rheumatology). In parallel, the company is developing its first clinical-stage asset, Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody for high-risk neuroblastoma.

Is Essential Pharma a public or private company?

Essential Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was Essential Pharma founded?

Essential Pharma was founded in 1985. It employs 101 to 250 people.

Where is Essential Pharma based?

Essential Pharma is headquartered in Egham, United Kingdom, in the Europe region.

How does Essential Pharma make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are in-licensing and Out-licensing.

Who are Essential Pharma's main competitors?

Broad incumbents on record are Viatris, Aspen Pharmacare, Jazz Pharmaceuticals, Leo Pharma, Mundipharma, Swedish Orphan Biovitrum (Sobi) and Recordati. Direct peers are Theramex and Clinigen Group. Leadiant Biosciences is listed as an emerging player.

Does Essential Pharma have an API?

No public API is recorded for Essential Pharma.

What industry is Essential Pharma in?

Essential Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialEssential Pharma And Nordmark Announce New Partnership And UK Availability Of Norzyme® (Pancreas Powder) 25,000 Gastro-Resistant Capsules For Pancreatic Exocrine InsufficiencyEssential Pharma and Nordmark announced a partnership to commercialise Nordmark's Norzyme pancreas powder capsules in the UK. The medicine received UK marketing authorisation and is now available for pancreatic exocrine insufficiency. The product is a pancreatic enzyme replacement therapy for patients with conditions like cystic fibrosis and chronic pancreatitis.GlobeNewswireEssential Pharma and Nordmark announce new partnership and UK availability of Norzyme® (pancreas powder) 25,000 gastro-resistant capsules for pancreatic exocrine insufficiencyEssential Pharma and Nordmark announced a partnership to commercialise Nordmark's Norzyme pancreas powder capsules in the UK. The medicine received UK marketing authorisation and is now available for pancreatic exocrine insufficiency. The product is a pancreatic enzyme replacement therapy for patients with conditions like cystic fibrosis and chronic pancreatitis.citybizVodori Adds Essential Pharma CEO Becki Morison to BoardVodori appointed Essential Pharma CEO Becki Morison to its board in August 2026, adding over 25 years of pharmaceutical leadership. She will work with EMEA leadership to support Europe expansion as Vodori develops its Regulated Content Intelligence Platform. The appointment strengthens Vodori's connection to pharmaceutical operating requirements.EIN PresswireVodori appoints Essential Pharma CEO Becki Morison to Board of DirectorsVodori appointed Becki Morison, CEO of Essential Pharma, to its Board of Directors in August 2026. Morison brings over 25 years of pharmaceutical leadership and will support Vodori's EMEA expansion. She will work closely with Vodori's EMEA VP and GM.The Pharma LetterEssential Pharma names Becki Morison as CEOEssential Pharma, a UK specialty pharmaceutical company, has appointed Becki Morison as chief executive officer, effective July 1, succeeding Simon Ball who has served as interim CEO since November 2025. The appointment is part of the company's strategy to expand its rare disease and established brands businesses. Simon Ball will remain president of Essential Pharma's Rare Disease business unit.GlobeNewswireEssential Pharma appoints Becki Morison as Chief Executive OfficerEssential Pharma has appointed Becki Morison as Chief Executive Officer, effective 1 July 2026, succeeding Simon Ball who served as interim CEO since November 2025 and will continue as President of the Rare Disease business unit. Morison brings over 25 years of pharmaceutical industry experience, having previously served as Executive Vice President at LEO Pharma and holding senior roles at Eli Lilly including leadership of the Neuroscience franchise. The company stated that with both its Established Brands and Rare Disease businesses now under dedicated leadership, Morison is positioned to drive the company's next phase of growth.GlobeNewswireRenaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastomaRenaissance Pharma Limited, an Essential Pharma subsidiary, has received FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A), enabling initiation of the SHINE Phase II/III clinical trial for high-risk neuroblastoma in pediatric patients. The company also successfully manufactured its first commercial-scale GMP batch of the drug, marking a key operational milestone as the programme advances toward potential commercialization. The antibody, targeting GD2 on neuroblastoma cells, builds on Phase II data showing an 86% overall survival rate at three years.GlobeNewswireEssential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertensionEssential Pharma acquired Ventavis (iloprost trometamol) and Breelib nebuliser rights from Bayer AG, excluding the USA and Russia. The product is available in over 60 markets and targets adult primary pulmonary hypertension. The deal expands Essential's rare disease portfolio.TipranksEssential Pharma announces acquisition of Ventavis from BayerEssential Pharma announced the acquisition of Ventavis and the Breelib nebuliser delivery technology from Bayer AG, expanding its specialty rare disease franchise. The treatment, a prostacyclin analogue for primary pulmonary hypertension, will be available across all global markets except the USA and Russia, with the product currently commercialised in over 60 markets. The transaction follows Essential Pharma's earlier acquisition of Colobreathe in early 2024, reinforcing the company's strategy to deliver medicines for underserved rare disease populations.GlobeNewswireEssential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership teamEssential Pharma appointed Simon Ramsden as Chief Financial Officer and Rob Smith as Chief Technology Officer, both with immediate effect. Ramsden brings over 20 years of pharmaceutical finance experience, including CFO at Resolution Therapeutics, while Smith has over 30 years in pharmaceutical operations and technology.